European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Behind every successful ecosystem is a group of experts helping shape its direction, ensure relevance, and maintain its focus on real-world impact.
At GIANT Health, this role is fulfilled by our Board of Advisors — a distinguished group of senior…
Procurement is no longer just a back-office function in healthcare — it is one of the most powerful levers shaping how the NHS adopts innovation, improves efficiency, and delivers better outcomes for patients.
At the heart of this transformation is…
Attendees
Sponsors and Exhibitors
Contact us